October 30, 2015
1 min read
Save

G-Eye HD colonoscopy improves CRC screening, surveillance

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

HONOLULU — G-Eye high-definition colonoscopy achieved a superior adenoma detection rate compared with standard high-definition colonoscopy in a randomized multicenter trial, according to a presenter at ACG 2015.

“This is a new technology platform where you’re using the same standard forward view colonoscope with a balloon integrated behind you,” which, when partially inflated during withdrawal, straightens colonic folds “to better see the colon topography and hopefully identify polyps,” Seth A. Gross, MD, FACG, from New York University Langone Medical Center, said during his presentation. “It also allows for some anchoring and it centralizes you when you’re doing your exam.”

To compare the polyp and adenoma detection rates of G-Eye HD colonoscopy (SMART Medical Systems) and standard HD colonoscopy, Gross and colleagues randomly assigned 400 patients aged older than 50 years, who were referred for screening or surveillance colonoscopy from May 2014 to May 2015, to undergo either procedure (G-eye, n = 204; standard, n = 196).

“This study actually is going to be expanded to 1,000 patients and those results will be finished later this year,” Gross said.

G-Eye HD colonoscopy achieved a 65% polyp detection rate vs. 43% with standard HD colonoscopy (51% higher), and a 52% adenoma detection rate vs. 32% with standard HD colonoscopy (62% higher). G-Eye HD colonoscopy also achieved a 56% higher number of advanced adenomas detected and a 55% higher number of large-size adenomas detected compared with standard HD colonoscopy.

G-Eye HD colonoscopy “has been shown in this study and prior studies to improve adenoma detection rate compared to standard colonoscopy and certainly will have downstream implications for future surveillance and management of your patients,” Gross said.” – by Adam Leitenberger 

Reference:

Gross SA, et al. Abstract 31. Presented at: ACG 2015; Oct. 19-21, 2015; Honolulu, HI.

Disclosures: Gross reports no relevant financial disclosures.